Cover Image
市場調查報告書

原發性免疫缺陷 (PID) :主要2之一市場的預測 2016-2026年

Primary Immunodeficiency Forecast in 21 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 355843
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
原發性免疫缺陷 (PID) :主要2之一市場的預測 2016-2026年 Primary Immunodeficiency Forecast in 21 Major Markets 2016-2026
出版日期: 2016年04月06日 內容資訊: 英文 76 Pages
簡介

原發性免疫缺陷症候群 (PID) ,是支配免疫系統的遺傳基因先天的遺傳基因疾病的一群。 PID,是身體的免疫系統有一部分欠缺,或作用不完善,有200個以上的罕見疾病、慢性疾病的一群。

本報告提供主要21個市場 (美國、法國、德國、義大利、西班牙、英國、巴西、日本、印度、瑞士、荷蘭、土耳其、瑞典、比利時、波蘭匈牙利、捷克、奧地利、希臘、阿根廷及墨西哥) 的青光眼的目前患者數 (性別、各年齡世代) 調查分析,目前盛行率,加上疾病概要,危險因素,疾病診斷與預後,主要的症狀和併發症等系統性資訊。

圖表

簡介

病因

危險因素和預防

疾病診斷

變異:各地區/民族

疾病預後和臨床過程

疾病相關的主要併發症/特徵

定量化患者數的手法

PID的最大患病人數

  • PID患者的分類
  • 有絕對性缺乏的PID患者的子類別
  • 有CD的PID患者的子類別
  • 有PID的其他明確定義的症候群
  • PID的SCID併發狀態

簡稱

相關出版

病患人數的線上資料庫

病患人數的產品

價格的線上資料、平台

參考文獻

附錄

目錄
Product Code: PRID0010416

image1

Primary immunodeficiency diseases (PID) are a group of inherited genetic disorders of the genes governing the immune system. PIDs are a group of more than 200 rare, chronic disorders in which part of the body's immune system is missing or functions improperly. Some types of PID affect a single part of the immune system while others may affect one or more components of the system.

This report provides the current prevalent population for PID disease across 21 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Switzerland, Netherlands, Turkey, Sweden, Belgium, Poland, Hungary, Czech Republic, Austria, Greece, Argentina and Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main syndromes and sub-classifications of PID have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PID include:

  • Severe Congenital Immunodeficiency (SCID)
  • Recurrent or persistent infections
  • Allergic manifestations
  • Respiratory diseases
  • Organ Problems
  • Developmental delay

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Please be aware that for some markets represented within this report, data is unavailable due to some markets being unable to report the same classifications and sub-classifications that are reported in other markets.

Reason to buy

  • Able to quantify patient populations in global PID's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of PID and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on PID's prevalent population.
  • Identify sub-populations within PID which require treatment.
  • Gain an understanding of the specific markets that have the largest number of PID patients.

Coverage

US, UK, FR, DE, IT, ES, JP, BR, IN, PL, TR, NL, AR, MX, CZ, GR, SE, CH, BE, HU, AT

image2

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions/ Features Associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Prevalence for PID

  • Classification of PID Patients
  • Subclassification of Primary Immunodeficient Patients with Ab Deficiency
  • Subclassification of PID Patients with CD
  • Other Well-Defined Syndromes with PID
  • SCID Co-morbid Condition within PID

Abbreviations used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Tables

  • Prevalence of PID, total (000s)
  • Prevalence of PID, males (000s)
  • Prevalence of PID, females (000s)
  • Classification of PID patients, total (000s)
  • Types of Ab Deficiency in PID patients, total (000s)
  • Types of Complement Deficiencies of PID patients, total (000s)
  • Types of Other Well-Defined Syndromes with PID patients, total (000s)
  • Types of SCID within PID, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of PID by 5-yr age cohort, males (000s)
  • USA Prevalence of PID by 5-yr age cohort, females (000s)
  • France Prevalence of PID by 5-yr age cohort, males (000s)
  • France Prevalence of PID by 5-yr age cohort, females (000s)
  • Germany Prevalence of PID by 5-yr age cohort, males (000s)
  • Germany Prevalence of PID by 5-yr age cohort, females (000s)
  • Italy Prevalence of PID by 5-yr age cohort, males (000s)
  • Italy Prevalence of PID by 5-yr age cohort, females (000s)
  • Spain Prevalence of PID by 5-yr age cohort, males (000s)
  • Spain Prevalence of PID by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of PID by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of PID by 5-yr age cohort, females (000s)
  • Brazil Prevalence of PID by 5-yr age cohort, males (000s)
  • Brazil Prevalence of PID by 5-yr age cohort, females (000s)
  • Japan Prevalence of PID by 5-yr age cohort, males (000s)
  • Japan Prevalence of PID by 5-yr age cohort, females (000s)
  • India Prevalence of PID by 5-yr age cohort, males (000s)
  • India Prevalence of PID by 5-yr age cohort, females (000s)
  • Switzerland Prevalence of PID by 5-yr age cohort, males (000s)
  • Switzerland Prevalence of PID by 5-yr age cohort, females (000s)
  • Netherlands Prevalence of PID by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of PID by 5-yr age cohort, females (000s)
  • Turkey Prevalence of PID by 5-yr age cohort, males (000s)
  • Turkey Prevalence of PID by 5-yr age cohort, females (000s)
  • Sweden Prevalence of PID by 5-yr age cohort, males (000s)
  • Sweden Prevalence of PID by 5-yr age cohort, females (000s)
  • Belgium Prevalence of PID by 5-yr age cohort, males (000s)
  • Belgium Prevalence of PID by 5-yr age cohort, females (000s)
  • Poland Prevalence of PID by 5-yr age cohort, males (000s)
  • Poland Prevalence of PID by 5-yr age cohort, females (000s)
  • Hungary Prevalence of PID by 5-yr age cohort, males (000s)
  • Hungary Prevalence of PID by 5-yr age cohort, females (000s)
  • CZR Prevalence of PID by 5-yr age cohort, males (000s)
  • CZR Prevalence of PID by 5-yr age cohort, females (000s)
  • Austria Prevalence of PID by 5-yr age cohort, males (000s)
  • Austria Prevalence of PID by 5-yr age cohort, females (000s)
  • Greece Prevalence of PID by 5-yr age cohort, males (000s)
  • Greece Prevalence of PID by 5-yr age cohort, females (000s)
  • Argentina Prevalence of PID by 5-yr age cohort, males (000s)
  • Argentina Prevalence of PID by 5-yr age cohort, females (000s)
  • Argentina Prevalence of PID by 5-yr age cohort, females (000s)
  • Mexico Prevalence of PID by 5-yr age cohort, females (000s)
  • Mexico Prevalence of PID by 5-yr age cohort, females (000s)
Back to Top